Content related to New cGMP Facility Aims to Accelerate Cell Therapy for Pediatric Cancer

The novel approach marks a significant step forward in developing CAR T-cell therapy for acute myeloid leukemia.

Dramatic advances in cancer research and treatment over the past two decades have made it possible for more children to survive a cancer diagnosis.

Chimeric antigen receptor (CAR) T-cell therapy uses a person’s own immune cells that have been modified to recognize and attack cancer cells.

A new study finds that blocking Artemis significantly reduces the proliferation of leukemia cells, without affecting normal cells.

Facing a new diagnosis? A pediatric oncologist explains what the care journey looks like for acute lymphoblastic leukemia, the most common form of childhood cancer.

A CHLA oncologist is leading new research to improve outcomes for children, adolescents and young adults with relapsed or treatment-resistant germ cell tumors.

A statistical analysis of the largest study cohort to date sheds light on improvements—and gaps—in post-relapse treatment for Acute Lymphoblastic Leukemia.

How next-generation gene therapies target the underlying causes of genetic diseases.

Historically, middle- and higher-income White families and individuals of European ancestry have been the vast majority of participants in clinical trials